Kashyap Patel, MD: A biosimilar is a compound that is produced by living organisms. It bears structural analytical similarities as well as chemical compositions that are pretty identical to the parent compound. It also has the similarity in the pharmacokinetics, pharmacodynamics, and immunogenicity. Safety- and efficacy-wise, it’s pretty identical to its parent biological compound. And they are different from generics. A generic is 1 simple chemical that could be broken out into multiple small tablets. The biosimilar is actually a lot more complex and complicated to manufacture.
Biosimilars, because they are a new class of drugs, the patients and physicians are still learning to understand what it is. The traditional concept is the biosimilars are identical to generics. That’s not the case. Again, there’s a more complicated process involving manufacturing, purifying, or identifying, analyzing, and evaluating a biosimilar.
Sometimes hundreds of millions of dollars are spent for biosimilar compounds because of the complexity of the way it’s manufactured. Physicians still are learning about that as a new class. The biosimilars came to the US market in 2016, and physicians are still learning about what they are. Patients are having difficulty coming to understand that they’re not inferior; there’s some perception that biosimilars are different. In terms of its efficacy, they are not. I think the FDA has provided a very rigorous path for a biosimilar in the pathway 351(k). But look at the totality of evidence. In my opinion, biosimilars are identical to parent compounds in terms of efficacy, safety, and, immunogenicity.
It’s somewhat more complicated and confusing compared with the parent compound, and I think there are genuine reasons. For the FDA to track down anything that is a biosimilar compound, they want to make sure that postapproval process, the FDA and the regulatory agencies can track the safety and efficacy of the biosimilar. Instead of giving all biosimilars 1 single name, because the FDA expects multiple companies to come in the same biosimilar space, they give a 4-letter [suffix] for safety and efficacy, as well as any adverse events to track down the biosimilar by the last 4 letters. That could be assigned to the unique Q code, so we could track the Q code and the last 4 letters attached to each biosimilar. Anything that’s led to that specific product can be tracked.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.